Up to one-third of all people with non-Hodgkin's lymphoma have diffuse large B-cell lymphoma (DLBCL). DLBCL grows quickly, but it's possible to cure it. Most people learn they have this type after ...

Blinatumomab has been shown to improve outcomes in children with relapsed B-cell ALL, but the effects in children with newly diagnosed disease have been unclear. New research findings are ...

During this test, the doctor removes part or all of a lymph node. A lab tests the sample for cancer. When B-cell lymphoma relapses, it usually causes symptoms. You may notice the same ones you had ...

Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

Intravascular large B-cell lymphoma (IVLBCL) is a rare type of non-Hodgkin’s lymphoma. Its symptoms can vary, making it difficult to diagnose. The outlook for people with IVLBCL is typically poor.

Clinical Trials of ADCs for the Treatment of B-cell Malignancies Five ADCs targeting ... including 19% with complete response in all patients and an ORR in 66% of patients with FL.

The US regulator has approved Aucatzyl (obecabtagene autoleucel or obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor ALL based on the results of the phase 2 FELIX ...